Related Experiment Video

Updated: May 6, 2026

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

12.6K

Acute exposure of beta-cells to troglitazone decreases insulin hypersecretion via activating AMPK

Ruyuan Deng1, Aifang Nie, Fangfang Jian

  • 1Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.

Biochimica Et Biophysica Acta
|October 23, 2013
PubMed
Abstract

Insights

Thiazolidinediones like troglitazone activate AMP-activated protein kinase (AMPK) to suppress insulin hypersecretion, protecting pancreatic beta cells. This mechanism helps restore glucose response and may prevent type 2 diabetes progression.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Metabolic Diseases

Background:

  • Insulin hypersecretion contributes to insulin resistance and type 2 diabetes.
  • Thiazolidinediones show promise in delaying pancreatic beta-cell dysfunction.
  • The precise mechanism of thiazolidinedione protection on beta-cells is not fully understood.

Purpose of the Study:

  • To investigate the effects of troglitazone on insulin secretion and AMP-activated protein kinase (AMPK) activity.
  • To elucidate the role of AMPK in the protective mechanisms of thiazolidinediones against beta-cell dysfunction.

Main Methods:

  • Isolated rat islets and MIN6 cells were used to assess insulin secretion and AMPK activity.
  • Troglitazone's effects were measured under varying glucose conditions.
  • AMPK inhibition (Compound C) and knockdown (AMPKα2) were employed to confirm the role of AMPK.

Main Results:

  • Troglitazone activated AMPK and suppressed high glucose-induced insulin hypersecretion.
  • AMPK activation by troglitazone was linked to restored glucose responsiveness after drug withdrawal.
  • Troglitazone modulated ion channel activity (KATP, potassium channels) and suppressed intracellular calcium responses, effects dependent on AMPK.

Conclusions:

  • Troglitazone activates AMPK, inhibiting insulin hypersecretion and providing beta-cells a "rest" to restore glucose response.
  • AMPK activation is a key mechanism by which thiazolidinediones preserve beta-cell function.
  • These findings support thiazolidinediones as potential therapeutic agents for managing type 2 diabetes.
Keywords:
ACCAMP-activated protein kinaseAMPKATP-sensitive K(+) channelBeta-cellGSISIFGIGTInsulin hyperscretionK(ATP)KvPPARγTZDTroglitazoneacetyl-CoA carboxylaseglucose-stimulated insulin secretionimpaired fasting glucoseimpaired glucose toleranceperoxisome proliferator-activated receptor γshRNAshort hairpin RNAthiazolidinedionesvoltage-dependent potassium channel

More Related Videos

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice08:01

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice

Published on: May 16, 2021

5.6K
Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

19.6K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
998
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
7.6K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.8K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K